Abstract

Breast cancer remains a significant global health challenge, necessitating the exploration of novel therapeutic strategies. Berberine, a natural alkaloid compound, has emerged as a promising candidate due to its diverse pharmacological activities, including anti-cancer effects. This article discusses recent research elucidating the mechanism by which berberine inhibits c-Jun phosphorylation and suppresses fibronectin expression in breast cancer cells. Activation of c-Jun and subsequent upregulation of fibronectin have been implicated in tumor progression and metastasis. The study reveals that berberine treatment effectively inhibits c-Jun phosphorylation, leading to a reduction in fibronectin expression and impairing the migratory and invasive potential of breast cancer cells. These findings highlight berberine’s potential as a therapeutic agent for breast cancer management by targeting key signaling pathways involved in tumor progression and metastasis. Further research is warranted to validate these findings and elucidate berberine’s full therapeutic potential in breast cancer therapy.